At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 68 target
Drug / intervention
Olutasidenib +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
In Brief
A Phase 2 clinical trial evaluating Olutasidenib, Cladribine (CLAD), and 4 other interventions for Targeted Therapy and 2 related conditions. Currently recruiting, targeting 68 participants across 1 site.
Detailed Summary
To learn about the safety and tolerability of study drug combinations in patients with relapsed/refractory, IDH1-mutated myeloid malignancies with a co-signaling mutation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTargeted Therapy, IDH1-Mutated Malignancies, Mutations
CountriesUnited States
CollaboratorsRigel Pharmaceuticals
Timeline
Phase 2Recruiting
2026202720282029
First PostedJun 2025
Enrollment StartSep 2025
TodayJul 2026
Primary CompletionJun 2027
Study CompletionJun 2029
First PostedJun 24, 2025
Enrollment StartSep 12, 2025
Primary CompletionJun 1, 2027
Study CompletionJun 1, 2029
TodayJul 1, 2026
Enrollment to primary: 1.7 yearsPosted 1.0 years agoPrimary completion in 11 months
Interventions
Olutasidenibdrug
Given by po
Cladribine (CLAD)drug
Given by IV
Venetoclaxdrug
Given by po
Gilteritinibdrug
Given by po
Ruxolitinibdrug
Given by po
Cytarabinedrug
Given SQ